McKesson stock trades near record levels as latest results highlight cash generation and oncology growth

McKesson Corporation (ISIN US58155Q1031) reported higher adjusted earnings and strong cash generation for its fiscal 2024, helping McKesson stock trade close to its record range on the New York Stock Exchange in recent months. According to the companys latest annual reporting for the year ended 31 March 2024, diluted adjusted earnings per share reached around $27 for fiscal 2024, compared with roughly $24 in fiscal 2023, reflecting double-digit growth driven by the US Pharmaceutical and Oncology segments.

Adjusted EPS up double digits

In its fiscal 2024 results, McKesson highlighted solid growth in adjusted earnings per share, underlining the cash-flow profile that many investors focus on in the healthcare distribution space. For the year ended 31 March 2024, diluted adjusted EPS of about $27 was roughly $3 higher than the prior year level of around $24, implying growth in the low double-digit percentage range as the company benefitted from increased specialty pharmaceutical volumes and oncology network expansion.

The companys reported revenue base is one of the largest in the US healthcare sector, with total fiscal 2024 revenue running in the hundreds of billions of dollars, reflecting its role as a major distributor of pharmaceuticals and medical supplies. McKesson also reported adjusted operating profit in the billions of dollars for fiscal 2024, with margins supported by its focus on higher-value specialty and oncology services rather than pure volume growth.

Alongside earnings growth, McKesson emphasized that its US Pharmaceutical segment delivered higher revenue year on year in fiscal 2024 as prescription volumes and specialty drug utilization increased. The company also continued to return capital to shareholders through share repurchases and dividends, with total capital returns in fiscal 2024 reaching several billion dollars according to company disclosures.

Free cash flow supports McKesson stock

Cash generation remains a central element of the equity story for McKesson stock. For fiscal 2024, McKesson reported operating cash flow in the billions of dollars, supporting free cash flow comfortably above $3 billion for the year. That free cash flow level was higher than in fiscal 2023, according to the companys commentary, giving McKesson room to fund acquisitions, technology investments and shareholder distributions while keeping its balance sheet relatively conservative.

Compared with historical levels, the fiscal 2024 free cash flow figure marks a clear improvement over the prior year, reflecting better working-capital management and steady profitability across core businesses. Management has highlighted that disciplined inventory and receivables management helped limit cash tied up in the distribution network, which in turn fed through to stronger cash generation.

McKesson has used this cash generation to reduce share count through repurchases. Over recent periods, the company has retired several million shares, meaning that the earnings growth per share partly reflects both operating progress and a lower number of shares outstanding. For investors, the combination of higher adjusted EPS and a shrinking share base reinforces the per-share value story.

Oncology and specialty growth

McKesson has been repositioning its business toward oncology and other specialty areas for several years, and fiscal 2024 figures indicate that this strategy is gaining traction. The companys oncology-focused networks and practices contributed a rising share of profit, with oncology and specialty services revenue increasing at a faster pace than the overall group. The oncology business now generates several billion dollars of annual revenue, compared with markedly lower levels a few years earlier, underscoring the shift in mix.

Within oncology, McKesson operates networks that support community practices, providing distribution, technology and services. Volumes of oncology medications and related therapies grew during fiscal 2024, which, combined with service fees, helped support profit margins in the segment. Management has noted that demographic trends and therapy innovation support a multi-year growth opportunity in oncology services.

Beyond oncology, McKesson also reports growth in specialty pharmaceutical distribution more broadly. Specialty products, including complex biologics and therapies requiring cold-chain handling or special monitoring, tend to offer higher margins than traditional primary-care medications. As the mix shifts toward these products, the companys profitability profile has improved compared with earlier periods when traditional volume distribution dominated.

Balance sheet and capital returns

McKessons fiscal 2024 balance sheet shows a combination of modest net debt and significant shareholder capital returns. Total debt stands in the low tens of billions of dollars, offset by cash and equivalents that keep leverage at levels management describes as prudent. Over the past fiscal year, McKesson allocated several billion dollars to share repurchases, continuing a multi-year pattern of capital returns.

In addition to buybacks, McKesson pays a recurring dividend. The fiscal 2024 dividend per share remained modest compared with the overall free cash flow, indicating that the company still favors repurchases for capital deployment. However, the dividend provides an income component and reinforces McKessons positioning as an established, cash-generative healthcare company rather than a purely growth-focused stock.

Investors tracking McKesson stock also often look at the relationship between free cash flow and total capital returns. In fiscal 2024, capital returned to shareholders, including buybacks and dividends, represented a significant portion of free cash flow but still left room for acquisitions and investment in technology platforms across the distribution network.

Revenue scale and margin profile

McKesson operates at a revenue scale that is unusual even among large-cap US healthcare companies. Fiscal 2024 revenue runs well above $200 billion, reflecting large volumes of drugs and medical products moving through its systems. Despite that scale, the companys margins remain relatively narrow in percentage terms because distribution is inherently low-margin, but the absolute dollar amount of profit and cash flow is significant.

Comparing fiscal 2024 with fiscal 2023, revenue grew by several percent, while adjusted operating profit increased at a faster pace due to mix enhancement. This means that margin expansion, measured as adjusted operating profit divided by revenue, contributed to the improvement in earnings per share. The companys focus on services and specialty products is a key driver of this margin story.

For investors, the margin narrative matters because McKesson faces competitive pressure from other distributors and from large customers. The fiscal 2024 figures suggest that despite such pressures, the company has been able to defend and in some areas improve its margin profile, helped by its scale, contracts, and investments in technology.

Positioning within healthcare distribution

McKesson remains one of the largest pharmaceutical distributors in the United States, operating alongside peers such as Cardinal Health and AmerisourceBergen in supplying pharmacies, hospitals and clinics. Its fiscal 2024 numbers underline the strength of the model: high revenue throughput, modest percentage margins but high absolute dollar cash generation.

Compared with some peers, McKesson has placed particular strategic emphasis on oncology and specialty services, which gives it exposure to areas that often grow faster than the broader market. The fiscal 2024 performance, with adjusted EPS up versus fiscal 2023 and free cash flow higher year on year, suggests that this strategy is not only defensively oriented but also capable of delivering growth.

In terms of risk, McKesson remains exposed to regulatory and pricing dynamics in the pharmaceutical market. However, the companys diversified customer relationships and long-term contracts help to stabilize volumes. The fiscal 2024 results show that even in a changing reimbursement environment, McKesson can sustain its earnings and cash flow profile.

Product focus: oncology services platform

One representative area of McKessons business model is its oncology services platform, which supports community oncology practices with drug distribution, technology solutions and practice management. This platform integrates distribution of oncology medications with data and support, helping physicians navigate complex treatment regimens and reimbursement structures.

Revenue from oncology services has been rising steadily, with fiscal 2024 figures indicating growth that outpaced the broader company revenue trend. As new oncology therapies reach the market, the need for reliable distribution and support infrastructure increases, and McKesson is positioned to benefit from that expansion. The oncology platform also provides cross-selling opportunities for technology and other services.

McKesson stock and market value

McKesson stock is listed on the New York Stock Exchange and has a market capitalization in the tens of billions of dollars, reflecting the companys position as a major component of the US healthcare sector. The shares have traded near historic high levels during recent months, supported by fiscal 2024 adjusted EPS growth of roughly $3 year on year and higher free cash flow compared with fiscal 2023.

The stock has also benefitted from broader investor interest in stable, cash-generative healthcare names at a time when some growth sectors face volatility. McKessons combination of scale, oncology and specialty exposure, and capital returns has contributed to its valuation, with the market assigning a premium relative to some more cyclical sectors. For shareholders, the key metrics to monitor remain adjusted EPS, free cash flow and the pace of oncology and specialty expansion.